NDAORALTABLETPriority Review
Approved
Apr 2016
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
63
Data completeness
5/8 — Partial
Priority Review
VENCLEXTA (venetoclax) by AbbVie is p-glycoprotein inhibitors [moa]. First approved in 2016.
Drug data last refreshed 18h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VENCLEXTA (venetoclax) is an oral BCL-2 inhibitor approved in 2016 for hematologic malignancies, currently in peak commercial lifecycle with $815M in Part D spending (2023). The drug works by inhibiting B-cell lymphoma-2 protein, triggering apoptosis in cancer cells. It is administered as an oral tablet and represents a foundational therapy in blood cancer treatment.
$0.815BPart D
Peak6.8 years to LOEProduct is at peak revenue with strong Medicare penetration (89,336 Part D claims in 2023), suggesting stable commercial team size and focus on market maintenance and indication expansion.
Mechanism of Action
P-Glycoprotein Inhibitors
Pharmacologic Class:
BCL-2 Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (63)
Axatilimab Combined With Decitabine/Venetoclax for the Treatment of TP53-mutated AML
Started Jan 2027
32 enrolled
Acute Myeloid LeukemiaTP53 Gene Mutation
Roginolisib Plus Obinutuzumab + Venetoclax in R/R CLL
Started Jan 2027
40 enrolled
Chronic Lymphocytic Leukemia (CLL)Refractory Chronic Lymphocytic Leukemia
Epcoritamab Plus Venetoclax Plus Ibrutinib in Patients With Chronic Lymphocytic Leukemia With TP53 Alterations
Started Dec 2026
44 enrolled
Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma
Nemtabrutinib and Venetoclax for the Treatment of Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Started Nov 2026
25 enrolled
Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma
A Study to Assess How Well the Study Medicine IPN60340 Works in Combination With Azacitidine and Venetoclax, Compared to Placebo in Combination With Azacitidine and Venetoclax, in Participants With Newly Diagnosed Acute Myeloid Leukemia Who Cannot Receive Intensive Chemotherapy
Started Nov 2026
540 enrolled
Acute Myeloid Leukaemia (AML)Acute Myeloid Leukaemia
Worked on VENCLEXTA at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.